Sartorius Stedim Biotech Stock Deutsche Boerse AG
Stocks
56S1
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
11:22:48 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 206.60 EUR | +4.13% |
|
+11.08% | -0.24% |
| 09-08 | Sartorius Stedim Biotech : Barclays remains its Buy rating | ZD |
| 08-20 | UBS Upgrades Sartorius Stedim Biotech to Buy, Boosts PT | MT |
| Market Cap | 20.08B 22.99B 18.86B 17.23B 32.33B 2,198B 32.32B 226B 87.29B 1,122B 86.3B 84.41B 3,619B | P/E 2026 * |
52.6x | P/E 2027 * | 40.9x |
|---|---|---|---|---|---|
| Enterprise Value | 22.09B 25.29B 20.75B 18.95B 35.56B 2,418B 35.55B 249B 96.02B 1,235B 94.93B 92.85B 3,981B | EV / Sales 2026 * |
7.06x | EV / Sales 2027 * | 6.3x |
| Free-Float |
28.47% | Yield 2026 * |
0.4% | Yield 2027 * | 0.49% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
OTC Markets
| SDMHF | Delayed | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Tradegate
| 56S1 | Real-time | |
|
Xetra
| 56S1 | Delayed | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
CBOE
| 0NK7 | Real-time | |
|
London S.E.
| 0NK7 | Delayed | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript: Sartorius Stedim Biotech
| 1 day | +4.13% | ||
| 1 week | +11.08% | ||
| Current month | +4.77% | ||
| 1 month | +6.22% | ||
| 3 months | +24.98% | ||
| 6 months | +20.54% | ||
| Current year | -0.24% |
| 1 week | 190.2 |  | 206.6 |
| 1 month | 183.6 | | 206.6 |
| Current year | 150.4 | | 223.4 |
| 1 year | 150.4 | | 223.4 |
| 3 years | 144.8 | | 280.5 |
| 5 years | 144.8 | | 535 |
| 10 years | 51.24 | | 553.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 2023-03-27 |
| Chief Tech/Sci/R&D Officer | 61 | 2011-09-07 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2015-04-06 | |
Susan Dexter
BRD | Director/Board Member | 69 | 2015-04-06 |
Lothar Kappich
BRD | Director/Board Member | 69 | 2017-09-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.13% | +11.08% | - | - | 22.5B | |
| +0.69% | +0.58% | -23.78% | +4.81% | 178B | |
| -1.07% | -3.23% | -4.53% | +12.81% | 117B | |
| -0.65% | -3.62% | +8.42% | +70.03% | 60.39B | |
| +1.27% | +0.05% | -2.16% | -30.95% | 49.22B | |
| -0.22% | +0.78% | +10.27% | +47.46% | 48.02B | |
| +0.40% | +5.73% | +32.74% | +0.51% | 33.65B | |
| +7.73% | +5.65% | - | - | 28.04B | |
| +2.57% | +4.47% | +45.61% | -0.86% | 25.46B | |
| +2.38% | +12.17% | +10.97% | -11.03% | 22.5B | |
| Average | +1.79% | +1.19% | +9.69% | +11.60% | 62.54B | |
| Weighted average by Cap. | +0.82% | -0.14% | -2.55% | +13.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.58B 2.94B 2.68B 5.03B 342B 5.03B 35.19B 13.59B 175B 13.44B 13.14B 564B | 3.47B 3.97B 3.26B 2.98B 5.58B 380B 5.58B 39.03B 15.08B 194B 14.91B 14.58B 625B |
| Net income | 381M 437M 358M 327M 614M 41.75B 614M 4.29B 1.66B 21.32B 1.64B 1.6B 68.73B | 483M 553M 454M 414M 778M 52.89B 778M 5.44B 2.1B 27B 2.08B 2.03B 87.07B |
| Net Debt | 2.01B 2.3B 1.89B 1.72B 3.23B 220B 3.23B 22.6B 8.73B 112B 8.63B 8.44B 362B | 1.76B 2.01B 1.65B 1.51B 2.83B 192B 2.83B 19.75B 7.63B 98.12B 7.54B 7.38B 316B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-22 | €206.60 | +4.13% | 30 |
| 26-09-21 | €198.40 | +1.59% | 0 |
| 26-09-18 | €195.30 | -0.26% | 0 |
| 26-09-17 | €195.80 | +2.94% | 75 |
| 26-09-16 | €190.20 | +3.59% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DIM Stock
- 56S1 Stock
Select your edition
All financial news and data tailored to specific country editions
